Our Perspectives are at the forefront of complex or emerging IP challenges, keeping you one step ahead.
The Issues we focus on target your recurring and strategic IP challenges, through cross-functional support.
We provide sector-specific support in a number of business areas historically linked to Regimbeau.
Regardless of the asset to be protected or enhanced, we have the right dedicated team to assist you.
For each type of company, Regimbeau provides tailor-made support, in line with its realities.
Our Perspectives are at the forefront of complex or emerging IP challenges, keeping you one step ahead.
The Issues we focus on target your recurring and strategic IP challenges, through cross-functional support.
We provide sector-specific support in a number of business areas historically linked to Regimbeau.
Regardless of the asset to be protected or enhanced, we have the right dedicated team to assist you.
For each type of company, Regimbeau provides tailor-made support, in line with its realities.
Immunotherapies, including monoclonal antibodies and checkpoint inhibitors, are a hugely promising therapeutic area, in terms of both clinical benefits and potential market size. These treatments are able to reactivate the body’s own immune response to increase effectiveness in fighting diseases, particularly cancers. Among immunotherapies “adoptive immunotherapies” such as CAR-T cells (T cells engineered with chimeric-antigen-receptors (CARs)) are probably the highest hopes for patients and turn out to be a hot topic for healthcare and pharmaceutical industries. CAR-T therapy is indeed a revolutionary type of treatment which has emerged as a potent new class of therapeutics for cancer, based notably on their remarkable potency in blood cancers.
Subscribe to our newsletter to receive our latest news